Home > Insider Trading > Filing (0000899243-22-033325)

Filing Details

Accession Number:: 0000899243-22-033325
Form Type:: 4/A
Zero Holdings:: No
Publication Time:: 2022-10-07 20:19:53
Reporting Period:: 2021-11-17

Accepted Time:: 2022-10-07 20:19:53
Original Submission Date:: 2022-10-04
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1830214	Ginkgo Bioworks Holdings Inc.	DNA	Biological Products, (No Disgnostic Substances) (2836)	872652913

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1883686	E. Marie Fallon	C/O Ginkgo Bioworks Holdings, Inc. 27 Drydock Avenue Boston MA 02210	See Remarks	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Class A Common Stock	Acquisiton	2022-09-30	6,134	$0.00	6,134	No	4	M	Direct
Class A Common Stock	Acquisiton	2022-10-01	226,376	$0.00	232,510	No	4	M	Direct
Class A Common Stock	Disposition	2022-10-03	2,722	$3.12	229,788	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Price - 2
Class A Common Stock	Class B Common Stock	Disposition	2022-09-30	6,134	$0.00	$0.00
Class A Common Stock	Restricted Stock Units	Acquisiton	2021-11-17	490,805	$0.00	$0.00
Class A Common Stock	Restricted Stock Units	Disposition	2022-10-01	226,376	$0.00	$0.00

Remaning Holdings	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
52,760	No	4	M	Direct
680,805	No	4	A	Direct
442,161	No	4	M	Direct

Footnotes

Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.
Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.
Represents restricted stock units (the "RSUs") granted prior to the business combination of Soaring Eagle Acquisition Corp. and Ginkgo Bioworks, Inc. in September 2021 (the "Merger"), which became contingent rights to acquire equity securities of the Issuer upon consummation of the Merger. At the time of grant, the RSUs were subject to both a service-based vesting condition and a performance-based vesting condition. On November 17, 2021, the board of directors of the Issuer modified the vesting terms of RSUs, such that the Merger was deemed to have satisfied the performance condition for vesting effective as of March 15, 2022. The service-based vesting condition with respect to 226,376 of the RSUs was satisfied on October 1, 2022, and the Issuer elected to deliver one share of Class A Common Stock to the Reporting Person for each such RSU. Such shares of Class A Common Stock may be exchanged for shares of Class B Common Stock at the option of the Reporting Person.
Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction.
Includes shares of Class B Common Stock that are subject to vesting conditions. Excludes RSUs, which were previously reported as shares of Class B Common Stock on the Form 4 filed by the reporting person on March 14, 2022. Because the Issuer has the ability to settle such RSUs with shares of Class A Common Stock or cash upon vesting, RSUs will be reported separately from shares of Class B Common Stock in future reports.
Includes RSUs that are subject to vesting conditions. Includes 190,000 RSUs that were acquired after November 17, 2021.